Emerging US Launch Shorla Oncology has already launched JYLAMVO in the US and is actively commercializing oncology and autoimmune products through a partnership with EVERSANA, indicating a ready-to-scale sales engine and potential for expansion of additional therapies in the US market.

US Regulatory Milestone FDA-approved oral methotrexate solution (JYLAMVO) positions Shorla as a specialized, niche oncology player with a proven pathway for US commercialization, suggesting opportunities for adjacent indications and dose forms within US payer networks.

Funding Momentum Recent $21M financing round signals investor confidence and potential for accelerated market access activities, salesforce expansion, and broader commercialization investments in key markets including the US and Ireland.

Leadership Brand Founders recognized with Future Leader award and a leadership team with clinical and commercial expertise create credibility with payers, providers, and KOLs, aiding opportunities for co-promotion, clinical collaborations, and market access discussions.

Focused Portfolio Strategic focus on underserved oncology indications and shortage or inadequacy of existing treatments positions Shorla to address high-need patient populations, enabling targeted outreach to hospitals, specialty pharmacies, and oncology networks seeking niche solutions.